Skip to main
  1. Stocks
  2. DarioHealth
  3. Forecast
DRIO

DarioHealth (DRIO) Stock Forecast & Price Target

DarioHealth (DRIO) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

DarioHealth is viewed positively because its vertically integrated platform combines FDA-cleared connected devices, proprietary AI, and coaching to address high-prevalence chronic conditions like diabetes, obesity, MSK, behavioral health, and sleep, creating a differentiated one-stop shop for employers and health plans. Its commercial traction appears meaningful, with 180+ clients, roughly 25% Fortune 500, access to more than 175M lives through plans and partnerships, and about 85 new clients added in 2025, while over 80% of ARR comes from multi-condition sales and 90% client retention supports visibility. Although 2025 and 1H:26 revenue declines reflect a planned shift away from bio-pharma and a legacy account loss, the company’s $13.1M of contracted new business and late-stage ARR, 62% gross margin in 2Q:26, and DarioIQ’s 13B+ data-point flywheel support improving revenue, margins, and cash flow.

Bears say

DarioHealth is facing a negative fundamental setup because it competes in a crowded digital health market for employers and payers, where differentiation on outcomes, pricing, and engagement is difficult and demand could shift toward other benefit categories. Revenue momentum also appears fragile: 2Q rev of $5.2M missed estimates, adj. EBITDA loss was $(5.3)M, and management has no official guidance, while $13M of new contracted ARR is not expected to begin ramping until 4Q and through 2027. Financial strain adds risk, with about $31M of debt versus ~$7M of cash in 2Q:26, and weaker digital health demand, churn, and potential dilutive capital raises could keep shares under pressure.

DarioHealth (DRIO) has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.

DarioHealth (DRIO) Analyst Forecast & Price Prediction

Get the latest DarioHealth (DRIO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DarioHealth (DRIO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DarioHealth (DRIO) Forecast

Analysts have given DarioHealth (DRIO) a Buy based on their latest research and market trends.

According to 4 analysts, DarioHealth (DRIO) has a Buy consensus rating as of Nov 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DarioHealth (DRIO)


DarioHealth (DRIO) Analyst Forecast & Price Prediction

Get the latest DarioHealth (DRIO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DarioHealth (DRIO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover DRIO stock data and trends